Hansa Biopharma Email Format
Biotechnology ResearchSkåne, Sweden51-200 Employees
Hansa Biopharma is a commercial-stage biotechnology company focused on developing immunomodulatory treatments for rare immune-related conditions. Its research targets outcomes in organ transplantation, IgG-mediated autoimmune diseases, and gene therapy, while also exploring potential cancer applications of its platform. Headquartered in Lund, in the Skåne region of Sweden, the company operates within the biotechnology research sector and aims to translate scientific insights into new therapies. Recently, Hansa Biopharma entered into an agreement with SERB Pharmaceuticals to transfer exclusive development and commercialization rights for Idefirix (imlifidase) to the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and the Middle East and North Africa region. This arrangement represents a significant regional rights transaction.